Neurogene Closes $115 Million Series B Financing
Proceeds from the financing will be used to advance Neurogene’s portfolio of multiple gene therapy programs into the clinic; accelerate investment in novel gene therapy product designs and Neurogene’s technology platform addressing key limitations in conventional gene therapy, and build out Neurogene’s state-of-the-art adeno-associated virus (AAV) vector GMP manufacturing capabilities.
“Gene therapy has generated tremendous hope for the many families and patients with severe genetic disorders. We believe our focus on improved product design, innovative technology, cutting-edge vector manufacturing and premier analytics will help fulfill the potential of genetic treatments,” said Rachel McMinn, Ph.D., Founder and Chief Executive Officer. “Proceeds from this round of financing will help us execute on our mission to develop safe and effective genetic therapies for patients and families living with neurological diseases.”
Oleg Nodelman, Founder and Portfolio Manager of EcoR1 Capital stated, “Neurogene is establishing itself as a leader in the gene therapy arena for neurological diseases. We are impressed by the Company’s innovation and accomplishments to date and are pleased to provide our support to Neurogene to advance medical research in this rapidly evolving area.”
About Neurogene Inc.
Neurogene Inc. is focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options currently exist. Our lead programs use adeno-associated virus (AAV) vector-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also developing novel gene therapy technologies to advance treatments for complex neurological diseases that conventional gene therapy cannot successfully address. For more information, visit www.neurogene.com.
Linda Phelan Dyson, MPH
Source: Neurogene Inc.